18F-FDG PET/MR对高危原发性乳腺癌患者治疗管理的影响——分期算法的前瞻性评估
这项来自两家大学医院的前瞻性队列研究纳入56例新诊断、未治疗且远处转移验前概率较高的乳腺癌女性,比较传统分期影像算法与18F-FDG PET/MR对TNM分类及治疗决策的影响;PET/MR分期使8/56例(14%)的治疗方案发生改变,PET/MR似乎分期更优但差异无统计学意义(p=0.3827)。
要点
- PET/MR分期使14%(8/56)的高危乳腺癌患者治疗方案发生改变,涉及乳腺、区域淋巴结和全身治疗。
- PET/MR较传统分期算法似乎分期更优,但差异无统计学意义(p=0.3827)。
- 指南修订背景下,作者认为该场景下仍需进一步评估18F-FDG PET/MR的真实价值。
核心结论
- 在高远处转移验前概率的乳腺癌患者中,经组织病理学确认,18F-FDG PET/MR分期较传统分期算法使14%的患者治疗方案发生改变;PET/MR似乎分期更优但未达统计学显著(p=0.3827)。
研究设计与样本
- 前瞻性队列研究,来自两家大学医院,纳入56例新诊断、未治疗且远处转移验前概率较高的乳腺癌女性。
诊断标准与关键数值
- 传统分期影像算法包括X线乳腺摄影、乳腺超声、胸部平片、骨闪烁显像及肝脏和腋窝超声;18F-FDG PET/MR包括全身扫描及专用乳腺PET/MR检查;以组织病理学为参考,比较两种算法对TNM分类的差异及治疗推荐改变。
临床应用与阅片要点
- 每例患者在独立的肿瘤委员会会议上讨论两次,基于原发肿瘤组织病理学数据分别形成三种治疗推荐:仅传统算法、传统算法联合18F-FDG PET/MR、仅18F-FDG PET/MR;作者认为指南修订背景下仍需进一步评估18F-FDG PET/MR在该场景中的真实价值。
局限性
- PET/MR较传统分期算法似乎分期更优,但差异无统计学意义(p=0.3827)。
- 作者指出,鉴于指南的修订,仍需进一步评估18F-FDG PET/MR在该场景中的真实价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate whether potential differences in staging between a traditional staging imaging algorithm and 18F-FDG PET/MR lead to a change in patient management in breast carcinoma and to compare the diagnostic accuracy between the traditional staging algorithm and 18F-FDG PET/MR for the TNM classification.
METHOD: In this prospective cohort study from two university hospitals 56 women with newly diagnosed, therapy-naive breast cancer and increased pre-test probability for distant metastases were included. All patients were examined by a traditional staging imaging algorithm (X-ray mammography, breast ultrasonography, chest plain radiography, bone scintigraphy, and ultrasonography of the liver and axillary fossa) and whole-body 18F-FDG PET/MR including dedicated 18F-FDG PET/MR breast examinations. Each patient was discussed two times in a separate tumor board session to determine a total of three therapy recommendations based on histopathological data of the primary tumor and (1) traditional algorithm only, (2) traditional algorithm and 18F-FDG PET/MR, and (3) 18F-FDG PET/MR only. Major changes in therapy recommendations and differences between the traditional staging algorithm and 18F-FDG PET/MR for the TNM classification were evaluated.
RESULTS: Staging by 18F-FDG PET/MR led to a difference in treatment compared the traditional staging algorithm in 8/56 cases (14%). Therapy changes included therapy of the breast, locoregional nodes and systemic therapy. A trend to staging superiority was found for 18F-FDG PET/MRI without statistical significance (p = 0.3827).
CONCLUSION: In conclusion, for breast cancer patients with elevated pre-test probability for distant metastases a change of the therapy regiment occurs in 14 % of patients when staged by 18F-FDG PET/MR and confirmed by histopathology compared to a traditional staging algorithm. In particular with regard to the amendment of the guideline further assessment of 18F-FDG-PET/MR in this setting is necessary to assess the true value of this modality.
引用
- Kirchner J, Martin O, Umutlu L, et al. Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithms. Eur J Radiol. 2020. PMID: 32371185. doi:10.1016/j.ejrad.2020.108975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。